Fordyce Marshall, PRES, reported an open-market or private sale at Vera Therapeutics, Inc. involving 18500.000000 shares for an estimated $649642.30. Reported holdings after the transaction were 235244.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
PRESIDENT AND CEO
The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.34, inclusive. The Reporting Person will provide upon request to th…
1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.
0 other filings
0 recent txs